SCHEMBL7561919

SCHEMBL7561919

O=C(NN=Cc1ncc[nH]1)c1[nH]c2ccccc2c1-c1cccs1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.45
KDM4E B2RXH2 6/20 0.45
POLB P06746 4/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
THRB P10828 1/20 0.45
ALDH1A1 P00352 6/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
LMNA P02545 5/20 0.41
HPGD P15428 3/20 0.41
PAX8 Q06710 2/20 0.41
HTT P42858 2/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7561917 1.00 MAPT (0.45) MAPTKDM4EPOLBMEN1KMT2A
SCHEMBL7557568 0.85 MAPT (0.55) MAPTKDM4EPOLBMEN1KMT2A
SCHEMBL7557566 0.85 MAPT (0.55) MAPTKDM4EPOLBMEN1KMT2A
SCHEMBL7678229 0.85 MEN1 (0.45) MAPTKDM4EPOLBMEN1KMT2A
SCHEMBL7678232 0.85 MEN1 (0.45) MAPTKDM4EPOLBMEN1KMT2A
SCHEMBL7561546 0.84 MAPT (0.49) MAPTKDM4EPOLBMEN1KMT2A
SCHEMBL7561550 0.84 MAPT (0.49) MAPTKDM4EPOLBMEN1KMT2A
SCHEMBL7561259 0.82 MAPT (0.44) MAPTKDM4EPOLBMEN1KMT2A
SCHEMBL7561263 0.82 MAPT (0.44) MAPTKDM4EPOLBMEN1KMT2A
SCHEMBL7563020 0.81 ALDH1A1 (0.59) MAPTKDM4EPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPT 4828/4885KDM4E 1608/4885POLB 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.